Phase 2 interim data analysis and commercial impact

The interim data from the Phase 2 clinical trial (LEGEND Pivotal Cohort) of enGene Therapeutics(ENGN)'s non-muscle invasive bladder cancer (NMIBC) gene therapy candidate, detalimogene voraplasmid (EG-70), has been released. The trial recorded a 6-month complete response rate (CRR) of 43% and an estimated 12-month duration of response (DoR) of 25%, significantly falling short of market expectations. Leerink Partners analysts, based on these disappointing efficacy results, have significantly reduced the company's unadjusted peak sales forecast from $1 billion (USD) to $350 million (USD). The target stock price has also been adjusted from $19 to $2, reflecting growing market skepticism about the potential for commercial success.

Widening efficacy gap with competing pipelines

This clinical data marks a turning point, highlighting a significant efficacy gap between detalimogene voraplasmid and competitors that have already been approved or are nearing commercialization. For example, Johnson & Johnson (JNJ)'s Inlexzo (gemcitabine intravesical system, TAR-200), a locally sustained-release gemcitabine delivery system, received FDA approval on September 9, 2025, and demonstrated an 82% complete response rate in clinical trials. Additionally, CG Oncology (CGON)'s cretostimogene grenadenorepvec (CG0070), a non-viral oncolytic immunotherapy, achieved a 6-month complete response rate of 63.6% in its Phase 3 trial (BOND-003), further solidifying its competitive advantage. The prevailing analysis suggests that the convenience of the dually derivatized oligochitosan (DDX) platform, which detalimogene voraplasmid boasts, is not enough to overcome this significant difference in therapeutic efficacy.

Re-evaluation of commercial penetration and cost-effectiveness

Leerink Partners analysts have slightly lowered the probability of approval from 70% to 60%, while still considering the approval of the new drug itself as viable. However, the commercial penetration in hospitals after approval will inevitably require a dramatic course correction. Previously, they had projected a 60% penetration rate in community hospitals and a 10% penetration rate in academic settings, but these figures have now been significantly reduced to 15% and 5%, respectively, following the data release. Although enGene Therapeutics may have advantages in terms of ease of administration and cost-effectiveness in the hospital setting, the fact that the recurrence rate is extremely high in the NMIBC market means that there are very limited reasons for physicians to choose a drug with only half the efficacy.

Delayed resolution of unmet needs and impact on patients and the market

The NMIBC market, which sees hundreds of thousands of new patients diagnosed worldwide each year, is in dire need of alternative bladder-sparing treatments for patients who do not respond to Bacillus Calmette-Guérin (BCG) immunotherapy, the current standard of care. The overall NMIBC treatment market is estimated to be approximately $3.6 billion to $3.87 billion in 2026, and there is a high unmet need, leading to intense competition in new drug development. However, the disappointing clinical results from enGene Therapeutics raise concerns that patients may have one fewer effective non-surgical bladder-sparing option. As a result, the market dominance of existing standard treatments and leading competitors, such as Johnson & Johnson's Inlexzo, is likely to be prolonged, which could have a somewhat negative impact on market diversification.

Deterioration of corporate financial health and venture capital sentiment

In addition to the reduction in projected sales, enGene Therapeutics' stock price plummeted to $1.72 after the data release, severely impacting its ability to raise capital in the short term. For a biotech venture company, the peak sales estimates based on clinical data are a key factor in future funding and partnership building, and this decline in value has significantly increased the cost of capital. In the short term, as the possibility of drug approval remains, the remaining data from the LEGEND trial needs to be reviewed for FDA submission. However, rather than pursuing independent commercialization, it is time to explore exit strategies such as additional licensing or combination trials with global pharmaceutical companies. In the future, it is likely to face a very conservative valuation in investment or M&A markets.